Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Colombian Journal of Anestesiology
versión impresa ISSN 0120-3347
Resumen
MOLTO, Luis et al. Is 1 mg/kg of sugammadex sufficient to reverse moderate neuromuscular block? A randomized clinical trial. Rev. colomb. anestesiol. [online]. 2019, vol.47, n.4, pp.211-218. Epub 16-Oct-2019. ISSN 0120-3347. https://doi.org/10.1097/cj9.0000000000000129.
Background:
Sugammadex has made it possible to reverse any type of rocuronium-induced block quickly and safely. The most frequent neuromuscular blockade is the moderate one where doses smaller than those recommended by the industry could get a full reversal.
Objective:
We aimed to evaluate the effectiveness of half the industry recommended dose of sugammadex to reverse a moderate neuromuscular block.
Methods:
Unicenter phase IV clinical trial that included 34 patients undergoing laparoscopic cholecystectomy. Intravenous general anesthesia was induced, with acceleromyographic monitoring of the neuromuscular block. After the intervention, the block was reversed with all or half the dose of sugammadex recommended for moderate blocks, using a blinded syringe.
Results:
Patient characteristics of the 2 groups were similar. Mean time to recovery was 3.6± 1.7minutes for the study group and 3.1 ± 1.7minutes for the control group (P=0.42). Reversal of the block was complete with a single dose of sugammadex in all patients. There was an important linear correlation between depth of block and time to recovery.
Conclusion:
Intraoperative monitoring is essential to allow us to individualize the dose of the neuromuscular blocking agent. To reverse a moderate block under neuromuscular monitoring, a dose of 1 mg/kg is sufficient in most cases and is equally safe and effective.
Palabras clave : Neuromuscular block; Residual block; Rocuronium; Sugammadex; Neuromuscular monitoring.